In recent years,interventional therapy combined with immunotherapy has become an important treatment method for primary hepatocellular carcinoma (HCC). Interventional therapy can promote tumor necrosis and enhance immunogenicity,while synergistic immunotherapy with interventional therapy can increase the clinical efficacy. Clinical studies have demonstrated that compared with single interventional therapy,interventional therapy combined with immunotherapy,and interventional therapy combined with targeted therapy and immunotherapy can significantly improve the tumor response rate,enhance the clinical efficacy,and prolong the survival time. In addition,the combination therapies can effectively convert unresectable HCC into resectable HCC,thereby improving treatment effectiveness. The combination therapies do not increase the incidence and severity of adverse reactions,and the its related adverse reactions are safe and controllable. Currently,most studies are retrospective studies with small samples. Therefore,more large-scale prospective randomized controlled clinical trials are needed to explore the optimal combination treatment strategies and the most suitable treatment population.
维普
万方数据